The 2025 European Society for Medical Oncology (ESMO) meeting was held October 17-21, 2025 in Berlin, Germany. Click the links below to read about research reported at this meeting that is of interest to people with MBC.
Triple-Negative MBC
- Breastcancer.org: Sacituzumab govitecan-hziy (Trodelvy®) provides longer progression-free survival than chemotherapy when given as the first treatment for metastatic triple-negative breast cancer (scroll to “Trodelvy may be new first treatment…”)
Hormone Receptor-Positive (HR+) MBC
- Targeted Oncology: An experimental antibody-drug conjugate called sacituzumab tirumotecan improves progression-free survival compared with chemotherapy in people with HR+, HER2- MBC
- OncoDaily: The experimental targeted therapy gedatolisib plus palbociclib (Ibrance®) and fulvestrant (Faslodex®) improved progression-free survival compared to palbociclib and fulvestrant in people with HR+, HER2- MBC whose cancer progressed while receiving a CDK4/6 inhibitor
- Cancer Network (article and video): Giredestrant and everolimus (Afinitor), both given by mouth, provide better survival and quality of life than hormone therapy and everolimus in people with HR+, HER2- MBC